Psyence Biomedical Ltd (NASDAQ: PBM) Now -99.68% Off Its High ($14.55), Does Analysts See Headwinds And Risks?

money audit

Psyence Biomedical Ltd (NASDAQ:PBM) currently has a daily average trading volume of 7.10M but it saw 7403358 shares traded in last market. With a market cap of 2.98M USD, the company’s current market price of $0.05 came falling about -6.00 while comparing to the previous closing price of $0.05. In past 52 weeks, the stock remained buoying in the range of price level as high as $14.55 and as low as $0.05. In the recent trading on the day, stock has struck highest price mark of $0.044 while lowest mark touched by it was $0.05.

Taking a look at 20-day trading activity of Psyence Biomedical Ltd (PBM) gives us an average price of $0.0686, while its current price level is -99.68% below from 52-week high level whereas it is 1.29% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.0939 while that of 200 days or SMA-200 reads an average of $0.5540. A closer look into the stock’s movement over the week reveals that its volatility is standing at 14.14% during that period while stretching the period over a month that increases to 16.52%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 27.57 which implies that the stock is in oversold territory.

Over the week, PBM’s stock price is moving -12.96% down while it is -56.03% when we observe its performance for the past one month. Year-to-date it is -99.49% down and over the past year, the stock is showing a downside performance of -99.58%.

The company is expected to be releasing its next quarterly report in December, for which analysts forecasted an EPS of 0 while estimate for next year EPS is 0.

Currently, Psyence Biomedical Ltd’s total number of outstanding shares is 54.33M with 11.14% of that held by the insiders while 5.74% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at 1.27%. Stock’s beta reads -0.50. Its return on asset (ROA) is 1.13% on average.